Skip to main content
Equibles
STIM logo

STIM · Neuronetics, Inc. · Metrics

Track STIM — free

Use STIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.39 -0.04 (-2.80%) At close · Nov 13 Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Therefore, substantial doubt exists about the Company’s ability to continue as a going concern. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period.”
View the 10-Q filed Nov 4, 2026
Market Cap
$108.04M
Shares
77.73M
Volume · Nov 13 16.26M Avg daily vol (3M) 1.64M

STIM metrics

90 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.39
Market cap
$108.04M

Price action

23 metrics
Price change (1W)
-35.3%
Price change (30D)
-28.7%
Price change (3M)
-57.9%
Price change (6M)
+8.6%
Price change (YTD)
+0.7%
Price change (1Y)
-31.9%
Trailing year
Price change (5Y)
-72.9%
52-week high
$3.30
52-week low
$1.18
Change from 52-week high
-57.9%
Change from 52-week low
+17.8%
Annualized volatility
119.8%
Annualized volatility (3M)
89.0%
Implied volatility (30D)
146.6%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.3
RSI (14D)
31.6
Price vs SMA 50
-40.8%
Price vs SMA 200
-25.7%
Avg volume (3M)
1.64M
Relative volume
9.9
Average dollar volume
$3.70M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
77.73M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.9×
reciprocal yield 108.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 147.9%
P / book
5.8
reciprocal yield 17.3%
FCF yield
-8.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.0×
reciprocal yield 49.1%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 62.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
50.7%
Operating margin
-9.4%
Trailing 12 months
Net margin
-14.6%
Gross profit (TTM)
$80.97M
Operating profit (TTM)
−$15.00M
Net income (TTM)
−$23.35M
Trailing 12 months
Diluted EPS (TTM)
$-0.33
FCF margin
-6.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.22
Gross profit per diluted share (TTM)
$1.12
Operating profit per diluted share (TTM)
$-0.22
EBITDA per diluted share (TTM)
$-0.17
Net income per diluted share (TTM)
$-0.33
Operating cash flow per diluted share (TTM)
$-0.12
Free cash flow per diluted share (TTM)
$-0.14
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.08
Stock compensation per diluted share (TTM)
$0.07
Book value per share
$0.32

Growth

11 metrics
Revenue growth YoY
+12.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$159.76M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.4%
Year over year · more shares
Revenue CAGR (3Y)
+31.8%
Revenue CAGR (5Y)
+24.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-124.8%
Return on assets
-17.7%
Debt / equity
3.3
Current ratio
2.0
EBITDA (TTM)
−$12.02M
Free cash flow (TTM)
−$9.61M
Quick ratio
1.8
Interest coverage
-1.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$39.65M
Latest balance sheet
Cash & equivalents
$22.11M
Total assets
$131.96M
Total debt
$61.75M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.31M
Capital expenditures (TTM)
$1.30M
R&D (TTM)
$5.56M
SG&A (TTM)
—
Stock compensation (TTM)
$4.72M
R&D / revenue
3.5%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
86
13F filer change QoQ
-13
Institutional ownership
48.0%
Conviction holders (share of 13F filers)
1.2%
Crowding (high-turnover and private-fund holders)
44.0%
Private-fund adviser ownership
41.1%
Active holders' share change QoQ
-5.2%
Holder tenure
5.8
Price vs estimated holder cost
-42.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.6%

Short interest

3 metrics
Short interest
8.6%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1227636 CUSIP 64131A105 13F (30d) 70 filings 57 filers Visit website